Business Wire

A Double Accolade for LOXAM’s CSR Policy: the 2019 Era Sustainability Award and EcoVadis Gold Certification

Share

On the occasion of the annual convention of the European Rental Association (ERA), held in Madrid on 15 and 16 May 2019, LOXAM received the Sustainability Award for its corporate programme to develop its Safety culture. This unprecedented approach is one of the initiatives conducted by LOXAM as part of its CSR policy in all 22 countries in which the Group operates.

In 2018, among the key pillars of its commitment to social responsibility, LOXAM chose to place emphasis on safety, a priority for the European equipment rental leader and a major issue for everyone, anytime and anywhere. As part of this safety focus, LOXAM launched the first edition of its in-house Safety Challenge, calling on contributions from nearly 8,000 employees all over the world (22 countries on 4 continents).

Through this challenge, the company’s management intended to raise awareness among the widest possible audience of the benefits of engaging in a process of “co-construction” combining individual and collective initiative.
Indeed, identifying issues and setting goals for Prevention and Safety are generally the responsibility of Management. On this occasion, the spotlight was directed towards the contribution of employees as the owners of practical and theoretical knowledge in their specific disciplines who advise their customers, repair equipment and travel for their personal and occupational needs.

This large-scale exercise, the first of its kind, is a perfect reflection of the priority that the LOXAM Group gives to safety and illustrates its desire to involve all employees in the firm, regardless of their job, country and culture. Safety is everyone’s business, and it is important that employees sense this responsibility to look after their own safety and that of other people.
This was perfectly borne out in the success of this first edition which received 272 entries from 770 participants based in France and abroad. The Challenge singled out and rewarded 28 proposals in 9 categories to improve safety everywhere and for everyone.

All the award-winning initiatives were subsequently studied in detail to determine the feasibility of their deployment across the entire Group in 2019.

This unprecedented in-house initiative conducted in the LOXAM Group is today acknowledged by the European rental community through the presentation of this ERA Sustainability Award.

LOXAM obtains EcoVadis Gold certification for its CSR policy
LOXAM has also received Gold certification from EcoVadis, the independent rating agency which assesses suppliers on sustainability and corporate social responsibility (CSR). The appraisal is based on international standards such as the United Nations Global Compact and the Global Reporting Initiative.

The Group has been ranked in the top 5% suppliers considered as the most advanced and committed to the sustainable management of the firm, whether in terms of the environment, labour, business ethics or sustainable procurement.

This accolade comes as acknowledgment of the continuous efforts of LOXAM and the commitment of its teams to all the areas falling within the scope of corporate social responsibility. LOXAM features among the firms receiving the highest ratings from EcoVadis, illustrating its compliance with the most stringent sustainability standards.

About the LOXAM Group
N° 1 in Europe and n° 5 in the world, LOXAM is the market leader in the rental of equipment and tools for building and public works, industry, landscaping and services. With sales of €1.5 billion in 2018, 760 branches and 7,900 employees, the Group is established in 13 countries in Europe (Belgium, Denmark, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Switzerland, United Kingdom), the Middle East, Morocco, Brazil and Colombia. LOXAM has the largest machine fleet in Europe, with more than 350,000 items of equipment to anticipate, support and fulfil the growing demand from companies that wish to outsource the procurement, management and maintenance of their equipment.
www.loxam.com

Contact information

Press contact:
Virginie Adam: +33 1 41 38 95 20
virginie.adam@salesfactorypr.fr

Dominique Flam: +33 1 41 38 95 21
dominique.flam@salesfactorypr.fr
www.agence-salesfactory-pr.fr
SalesFactory PR

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 20:59:00 EESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 16:05:00 EESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 15:30:00 EESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 14:00:00 EESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 13:46:00 EESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 13:00:00 EESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom